Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. AN2 Therapeutics Inc shares valued at $5,578 were sold by Day Lucy on Jan 06 ’26. At $1.01 per share, Day Lucy sold 5,512 shares. The insider’s holdings dropped to 75,363 shares worth approximately $99479.16 following the completion of this transaction.
Also, Day Lucy sold 3,295 shares, netting a total of over 3,305 in proceeds. Following the sale of shares at $1.00 each, the insider now holds 80,875 shares.
Before that, Prior Stephen David had sold 3,604 shares from its account. In a trade valued at $3,615, the Chief Strategy Officer traded AN2 Therapeutics Inc shares for $1.00 each. Upon closing the transaction, the insider’s holdings decreased to 3,604 shares, worth approximately $81766.08.
As published in a research note from Leerink Partners on August 09, 2024, AN2 Therapeutics Inc [ANTX] has been rated down from an Outperform to a Market perform and the price target has been revised to $1 from $5. Analysts at Evercore ISI downgraded the stock from ‘”an In-line”‘ to ‘”an Underperform”‘ outlook in a report released in early August. As of July 03, 2024, Leerink Partners has increased its “Market perform” rating to a “an Outperform” for ANTX. Earlier on April 02, 2024, JMP Securities upgraded its rating. Their new recommendation was “a Mkt outperform” for ANTX stock which previously was a “a Mkt perform”.
Analyzing ANTX Stock Performance
On last trading session, AN2 Therapeutics Inc [NASDAQ: ANTX] rose 20.00% to $1.32. The stock’s lowest price that day was $1.08, but it reached a high of $1.3499 in the same session. During the last five days, there has been a surge of approximately 15.79%. Over the course of the year, AN2 Therapeutics Inc shares have dropped approximately -4.35%. Shares of the company reached a 52-week high of $1.3499 on 01/08/26 and a 52-week low of $1.0000 on 01/05/26.
Support And Resistance Levels for AN2 Therapeutics Inc (ANTX)
According to the 24-hour chart, there is a support level at 1.1500, which, if violated, would cause prices to drop to 0.9801. In the upper region, resistance lies at 1.4199. The next price resistance is at 1.5199. RSI (Relative Strength Index) is 69.36 on the 14-day chart, showing neutral technical sentiment.
Is AN2 Therapeutics Inc subject to short interest?
Stocks of AN2 Therapeutics Inc saw a sharp steep in short interest on 2025-12-15 dropping by 6177.0 shares to 41353.0. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 47530.0 shares. A decline of -14.94% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 0.69 of the overall float, the days-to-cover ratio (short ratio) decline to 0.69.
Which companies own the most shares of AN2 Therapeutics Inc (ANTX)?
In terms of AN2 Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 3.5 in the next 12 months, up nearly 218.18% from the previous closing price of $1.1. Analysts anticipate AN2 Therapeutics Inc stock to reach 22 by 2026, with the lowest price target being 2. In spite of this, 3 analysts ranked AN2 Therapeutics Inc stock as Buy at the end of 2026. On February 13, 2024, Leerink Partners assigned a price target of “a Market perform” to the stock and downgraded coverage with a $7.
